Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade F 3.61 1.12% 0.04
AGEN closed up 1.12 percent on Monday, August 21, 2017, on 45 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AGEN trend table...

Date Alert Name Type % Chg
Aug 21 NR7 Range Contraction 0.00%
Aug 21 NR7-2 Range Contraction 0.00%
Aug 21 Narrow Range Bar Range Contraction 0.00%
Aug 18 NR7 Range Contraction 1.12%
Aug 18 Narrow Range Bar Range Contraction 1.12%

Older signals for AGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.49
52 Week Low 3.2
Average Volume 1,182,929
200-Day Moving Average 4.0255
50-Day Moving Average 4.1011
20-Day Moving Average 4.0323
10-Day Moving Average 3.635
Average True Range 0.2447
ADX 27.77
+DI 16.91
-DI: 24.78
Chandelier Exit (Long, 3 ATRs) 4.7159
Chandelier Exit (Short, 3 ATRs) 4.1541
Upper Bollinger Band 5.0521
Lower Bollinger Band 3.0125
Percent B (%b) 0.29
Bandwidth 0.505816
MACD Line -0.2099
MACD Signal Line -0.1545
MACD Histogram -0.0555